Sientra, Inc. (NASDAQ:SIEN) Stock Rating Lowered by Zacks Investment Research
Sientra, Inc. (NASDAQ:SIEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Several other equities research analysts have also commented on SIEN. Lake Street Capital initiated coverage on Sientra in a research note on Monday, April 17th. They set a “buy” rating and a $11.00 price target for the company. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Stephens began coverage on Sientra in a research note on Tuesday, July 11th. They set an “overweight” rating and a $12.00 price target for the company.
Sientra (SIEN) opened at 10.48 on Tuesday. Sientra has a one year low of $6.92 and a one year high of $11.47. The company’s 50-day moving average price is $10.48 and its 200-day moving average price is $8.97. The stock’s market capitalization is $200.50 million.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.04. The company had revenue of $8.20 million during the quarter, compared to analyst estimates of $6.97 million. Sientra had a negative return on equity of 52.30% and a negative net margin of 173.83%. Sientra’s quarterly revenue was up 32.3% compared to the same quarter last year. Equities research analysts predict that Sientra will post ($2.31) EPS for the current year.
Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in shares of Sientra during the second quarter valued at $101,000. Mission Wealth Management LLC bought a new stake in shares of Sientra during the first quarter valued at $104,000. Nationwide Fund Advisors increased its stake in shares of Sientra by 260.4% in the second quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 7,921 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 40 shares during the last quarter. Finally, Accredited Investors Inc. bought a new stake in shares of Sientra during the second quarter valued at $115,000. 78.57% of the stock is owned by institutional investors.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.